JP2017519008A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519008A5
JP2017519008A5 JP2016572697A JP2016572697A JP2017519008A5 JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 2017519008 A5 JP2017519008 A5 JP 2017519008A5
Authority
JP
Japan
Prior art keywords
serelaxin
pharmaceutical formulation
patient
biological sample
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519008A (ja
JP6820748B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054399 external-priority patent/WO2015189790A1/en
Publication of JP2017519008A publication Critical patent/JP2017519008A/ja
Publication of JP2017519008A5 publication Critical patent/JP2017519008A5/ja
Application granted granted Critical
Publication of JP6820748B2 publication Critical patent/JP6820748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016572697A 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用 Expired - Fee Related JP6820748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (3)

Publication Number Publication Date
JP2017519008A JP2017519008A (ja) 2017-07-13
JP2017519008A5 true JP2017519008A5 (cg-RX-API-DMAC7.html) 2018-07-19
JP6820748B2 JP6820748B2 (ja) 2021-01-27

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572697A Expired - Fee Related JP6820748B2 (ja) 2014-06-13 2015-06-10 Gdf−15を減少させるためのセレラキシンの使用

Country Status (11)

Country Link
US (2) US20170100460A1 (cg-RX-API-DMAC7.html)
EP (1) EP3154559B1 (cg-RX-API-DMAC7.html)
JP (1) JP6820748B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170018829A (cg-RX-API-DMAC7.html)
CN (1) CN106413740A (cg-RX-API-DMAC7.html)
AU (2) AU2015273097A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016028833A2 (cg-RX-API-DMAC7.html)
CA (1) CA2952061A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016016414A (cg-RX-API-DMAC7.html)
RU (1) RU2016147122A (cg-RX-API-DMAC7.html)
WO (1) WO2015189790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
FI3628049T3 (fi) 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
CN114025675A (zh) * 2019-06-20 2022-02-08 索尼集团公司 信息处理装置、信息处理方法和程序

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000914A (es) * 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
EA201500552A1 (ru) * 2008-05-16 2016-07-29 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
JP2017519008A5 (cg-RX-API-DMAC7.html)
Myles et al. Importance of intraoperative oliguria during major abdominal surgery: findings of the restrictive versus liberal fluid therapy in major abdominal surgery trial
Guo et al. Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1–mediated neutrophilic acute lung inflammation
Ter Maaten et al. Diuretic response in acute heart failure—an analysis from ASCEND-HF
Yanishi et al. Factors associated with the development of sarcopenia in kidney transplant recipients
Peck-Radosavljevic et al. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)
Behr The diagnosis and treatment of idiopathic pulmonary fibrosis
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
Rodríguez et al. Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit
Karavanaki et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis
JP2016520573A5 (cg-RX-API-DMAC7.html)
Zhang et al. The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism
Sarma et al. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease
Lazzeri et al. Mechanical ventilation in the early phase of ST elevation myocardial infarction treated with mechanical revascularization
Nazim et al. Metabolic control and its variability are major risk factors for microalbuminuria in children with type 1 diabetes
Zhang et al. Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients
Gores et al. Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy
Sharma et al. Alveolar macrophage activation in obese patients with obstructive sleep apnea
Mederacke et al. Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection
Roberts et al. A novel way to investigate the effects of plasma exchange on antibiotic levels: Use of microdialysis
Boussir et al. Eosinophilic myocarditis and hypereosinophilic syndrome
Rouini et al. Oral substitution of melatonin in critical care: a pharmacokinetic study in patients with intracranial hemorrhage
Elder et al. Prevention and amelioration of rodent endotoxin-induced lung injury with administration of a novel therapeutic tripeptide feG
Shinohara et al. Telmisartan effectively improves insulin sensitivity in hypertensive patients with insulin resistance